GYRE on Nasdaq

GYRE THERAPEUTICS, INC.

American pharmaceutical preparations company based in San Diego. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with UroGen Pharma Ltd., ImmunoGen Inc. or Xencor Inc, or pick any stock.

  • TickerGYRE on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersWinston-Salem, United States2
  • Incorporated inDE3
  • Business address12730 High Bluff Drive, Suite 250, San Diego, Ca 921303
  • Filer categoryAccelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300TE6BBPJ0S88K482
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 27259402

See how the biggest companies compare on our leaderboards

In this section, unless otherwise specified, references to “we,” “our,” “us” and “our company” refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (“Gyre Pharmaceuticals”).4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

9.9%Operating margin5
8.5%Net margin5
10.2%Revenue growth, 20255
9.3%Return on equity5
-$180.0KFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue5¢$5.4M
  • Research and development12¢$13.7M
  • Other costs71¢$83.0M
  • Income tax4¢$4.6M
  • Profit8¢$9.9M

Out of $116.6M in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Capital spending100¢$1.2M

Out of $1.0M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.5

Financial statements

Revenue6785$116.6M in 2025+457% since 2020
0$50.0M$100.0M$150.0M2020: $20.9M$20.9M20202021: $7.3M$7.3M2021−65%2022: $102.3M$102.3M2022+1294%2023: $113.5M$113.5M2023+11%2024: $105.8M$105.8M2024−7%2025: $116.6M$116.6M2025+10%
Gross profit78$101.9M in 2024+4% since 2022
0$50.0M$100.0M$150.0M2022: $97.5M$97.5M20222023: $108.8M$108.8M2023+12%2024: $101.9M$101.9M2024−6%
Operating income9610785$11.5M in 2025
-$100.0M-$50.0M0$50.0M2019: -$57.3M-$57.3M20192020: -$57.4M-$57.4M2020+0%2021: -$87.9M-$87.9M2021+53%2022: $9.2M$9.2M20222023: -$67.2M-$67.2M20232024: $16.2M$16.2M20242025: $11.5M$11.5M2025−29%
Net income9610785$9.9M in 2025
-$100.0M-$50.0M0$50.0M2019: -$55.2M-$55.2M20192020: -$56.2M-$56.2M2020+2%2021: -$87.9M-$87.9M2021+56%2022: $4.3M$4.3M20222023: -$85.5M-$85.5M20232024: $17.9M$17.9M20242025: $9.9M$9.9M2025−45%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenues$116.6M$105.8M
Cost of revenues$5.4M$3.9M
Selling and marketing$65.2M$57.5M
Research and development$13.7M$12.0M
General and administrative$20.8M$16.1M
Loss on disposal of assets, net$4.0K$66.0K
Total operating expenses$105.1M$89.6M
Income from operations$11.5M$16.2M
Interest income, net$1.7M$1.5M
Other expense, net-$1.5M-$1.7M
Change in fair value of warrant liability$2.7M$7.2M
Total income before income taxes$14.4M$23.2M
Provision for income taxes-$4.6M-$5.3M
Net income$9.9M$17.9M
Net income attributable to noncontrolling interest$4.9M$5.8M
Net income attributable to common stockholders$5.0M$12.1M
Net income per share attributable to common stockholders, basic$0.06$0.14
Net income per share attributable to common stockholders, diluted$0.02$0.05
Weighted average shares used in calculating net income per share attributable to common stockholders, basic89.3M shares85.1M shares
Weighted average shares used in calculating net income per share attributable to common stockholders, diluted103.2M shares102.3M shares
Foreign currency translation adjustments$2.6M-$1.5M
Comprehensive income from operations$12.5M$16.4M
Foreign currency translation adjustments attributable to noncontrolling interest$818.0K-$507.0K
Comprehensive income attributable to noncontrolling interest$5.7M$5.3M
Comprehensive income attributable to common stockholders$6.8M$11.1M

Compare GYRE THERAPEUTICS, INC. with another company

Leadership

Who has led GYRE THERAPEUTICS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. J. Donald Debethizy2006–2012
  2. Stephen A. Hill2012–2015
  3. Nassim Usman2015–2023
  4. Charles C. Wu2023
  5. Han Ying2024

Chair

  1. Mark B. Skaletsky2012

President

  1. J. Donald Debethizy2006–2012
  2. Stephen A. Hill2012–2015
  3. Nassim Usman2015–2023
  4. Songjiang Ma2023–now

Chief financial officer

  1. Alan A. Musso2006–2014
  2. Mauri K. Hodges2014–2015
  3. Fletcher Payne2015–2019
  4. Clinton Musil2020–2021
  5. Seline E. Miller2021–2023
  6. Ruoyu Chen2023–2026
  7. Thomas Wilson Eastling2026–now

Chief operating officer

  1. Weiguo Ye2023–now
2010201520202025
Board members and other officers (50)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerWeiguo Yu named Nov 13, 202374
  • DirectorUsman G. Nassim named Nov 13, 202374
  • DirectorYing Luo named Nov 13, 202374

Former names

  • CATALYST BIOSCIENCES, INC.Jun 23, 2015 to Oct 27, 20233
  • TARGACEPT INCDec 16, 2002 to Aug 19, 20153

Timeline

  1. Aug 16, 2024New chief executive Han Ying becomes CEO14
  2. Nov 1, 2023New chief executive Charles C. Wu becomes CEO15
  3. Aug 20, 2015New chief executive Nassim Usman becomes CEO16
  4. Dec 5, 2012New chief executive Stephen A. Hill becomes CEO17
  5. Apr 11, 2006New chief executive J. Donald Debethizy becomes CEO18
  6. Mar 7, 1997Founded GYRE THERAPEUTICS, INC. is founded2

Filings

415 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 83 major events, 150 insider forms, 43 large holders, 1 private raises, 117 other. The latest 20:

  1. Sep 1, 20268-K EDGAR
  2. Aug 31, 2026S-8 EDGAR
  3. Aug 26, 20268-K EDGAR
  4. Aug 7, 202610-Q EDGAR
  5. Aug 7, 20268-K EDGAR
  6. Aug 4, 20264 EDGAR
  7. Aug 4, 20264 EDGAR
  8. Aug 4, 20263 EDGAR
  9. Aug 4, 20263 EDGAR
  10. Aug 3, 2026EFFECT EDGAR
  11. Jul 16, 20268-K EDGAR
  12. Jul 15, 20268-K/A EDGAR
  13. Jul 13, 2026S-3/A EDGAR
  14. Jun 30, 20264 EDGAR
  15. Jun 30, 20264 EDGAR
  16. Jun 30, 20264 EDGAR
  17. Jun 30, 20264 EDGAR
  18. Jun 30, 20264 EDGAR
  19. Jun 30, 20264 EDGAR
  20. Jun 23, 2026S-3 EDGAR

The 415 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

105 open-market trades by officers, directors and large owners since October 2021: 6 buys and 99 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 18, 2026Ye WeiguoChief Operating OfficerSale3,000$6.35$19.1KForm 4
Jun 11, 2026Ye WeiguoChief Operating OfficerSale2,800$6.17$17.3KForm 4
Jun 10, 2026Ye WeiguoChief Operating OfficerSale5,000$6.24$31.2KForm 4
Jun 10, 2026Ye WeiguoChief Operating OfficerSale6,418$6.21$39.9KForm 4
Jun 9, 2026Ye WeiguoChief Operating OfficerSale3,000$6.15$18.4KForm 4
Jun 9, 2026Ye WeiguoChief Operating OfficerSale14,500$6.14$89.0KForm 4
Jun 5, 2026Ye WeiguoChief Operating OfficerSale15,401$6.40$98.6KForm 4
Jun 4, 2026Ye WeiguoChief Operating OfficerSale19,575$6.13$120.0KForm 4
May 26, 2026Ye WeiguoChief Operating OfficerSale4,000$6.10$24.4KForm 4
May 22, 2026Ye WeiguoChief Operating OfficerSale3,500$6.08$21.3KForm 4
May 21, 2026Ye WeiguoChief Operating OfficerSale12,820$6.15$78.8KForm 4
May 20, 2026Ye WeiguoChief Operating OfficerSale9,400$6.15$57.8KForm 4
May 19, 2026Ye WeiguoChief Operating OfficerSale9,120$6.37$58.1KForm 4
May 18, 2026Ye WeiguoChief Operating OfficerSale200$6.62$1.3KForm 4
May 15, 2026Ye WeiguoChief Operating OfficerSale13,100$6.65$87.1KForm 4
May 14, 2026Ye WeiguoChief Operating OfficerSale15,580$6.91$107.7KForm 4
May 6, 2026Luo YingChief Executive OfficerSale10,136$8.04$81.5KForm 4
May 5, 2026Luo YingChief Executive OfficerSale179$8.01$1.4KForm 4
May 28, 2025Ma SongjiangPresidentSale558$10.07$5.6KForm 4
May 27, 2025Ma SongjiangPresidentSale2,000$10.28$20.6KForm 4

All 105 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 30, 2023Raised $5 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 60. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
HSG Holding Ltd3,750,299$24.7M2.1%New
BlackRock, Inc.993,943$6.6M0.0%+235,313
Octagon Capital Advisors LP954,416$6.3M0.6%New
Vanguard Capital Management LLC876,927$5.8M0.0%−107,277
Geode Capital Management, LLC532,950$3.5M0.0%+101,536
State Street Corp245,402$1.6M0.0%+29,076
Charles Schwab Investment Management Inc184,286$1.2M0.0%+19,048
Northern Trust Corp169,537$1.1M0.0%+35,696
SBI Securities Co., Ltd.166,750$1.1M0.0%−4,087
Vanguard Fiduciary Trust Co151,073$995.6K0.0%+13,391
Vanguard Portfolio Management LLC123,953$816.9K0.0%+54,139
Goldman Sachs Group Inc86,235$568.3K0.0%+13,113
Bank of New York Mellon Corp62,750$413.5K0.0%+19,606
Morgan Stanley41,691$274.7K0.0%+33,050
Alliancebernstein L.P.24,590$171.4K0.0%+2,760
Strs Ohio25,800$170.0K0.0%+4,700
Dimensional Fund Advisors LP25,268$166.5K0.0%No change
Nuveen, LLC24,505$161.5K0.0%New
UBS Group AG18,763$123.6K0.0%−2,324
Millennium Management LLC18,488$121.8K0.0%New
Deutsche Bank Ag\17,939$118.2K0.0%+7,326
Rhumbline Advisers16,865$111.1K0.0%+3,749
Wells Fargo & Company/mn16,297$107.4K0.0%+12,007
Fmr LLC14,974$98.7K0.0%−3,743
Royal Bank Of Canada13,195$87.0K0.0%+7,590

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86